California State Teachers Retirement System raised its holdings in shares of Liquidia Corporation (N

Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy

Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new gr

Liquidia stock rises after the FDA grants Fast Track status to YUTREPIA for treating Raynaud’s pheno

Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to

Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-a

MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biophar

MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today anno

Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies c

Investors need to pay close attention to LQDA stock based on the movements in the options market lat

On August 28, 2026, Liquidia Corp (LQDA) shares experienced a decline of 3.1%, bringing the current

Liquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ va

Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make

LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to

On August 20, 2026, Liquidia Corp (LQDA) shares fell 5.8% to $71.05, continuing a downward trend fro

Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-

Handelsbanken Fonder AB bought a new stake in Liquidia Corporation (NASDAQ: LQDA) during the second

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product de

The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the compan

Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broad

Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise

Top analysts changed outlook on top names. Truist, Morgan Stanley, B of A Securities, HC Wainwright,

B of A Securities analyst Jason Gerberry maintains Liquidia (NASDAQ:LQDA) with a Neutral and rais

YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% seq

LifeSci Capital analyst Gaurav Maini downgrades Liquidia (NASDAQ:LQDA) from Outperform to Market

Needham analyst Serge Belanger maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price t

BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price tar

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Liquidia (NASDAQ:LQDA) reported quarterly earnings of $0.74 per share which beat the analyst consens

HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra

Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,

Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrad

B of A Securities analyst Jason Gerberry downgrades Liquidia (NASDAQ:LQDA) from Buy to Neutral an

Liquidia (NASDAQ:LQDA) released first-quarter financial results and hosted an earnings call on Monda

BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price tar

Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to

HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra

Liquidia Corp (LQDA) reported better-than-expected Q1 results, with earnings of 52 cents per share a

Wall Street analysts changed outlook on top names. For full view of analyst rating changes, see anal

HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra

Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise

Needham analyst Serge Belanger maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price t

BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price tar

US stocks rise, Nasdaq up 0.3%. Liquidia Corp (LQDA) beats Q1 expectations, shares rise 15.7%. Other

Liquidia (NASDAQ:LQDA) reported quarterly earnings of $0.52 per share which beat the analyst consens

Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise

Oppenheimer analyst Andreas Argyrides maintains Liquidia (NASDAQ:LQDA) with a Underperform and ra